Product Dossier
CLAVAMOX
Product Dossier for CLAVAMOX (amoxicillin, clavulanic acid, Pharmacor). ARTG record, PBS listing, PBAC outcomes — compiled by arcimedes.
- Sponsor: Pharmacor
- Active ingredient: amoxicillin, clavulanic acid
- Therapeutic area: Infectious Disease
- Related brand: AMOXIL
- Related brand: MAXAMOX
- Related brand: APO-AMOXYCILLIN
- Same area: RETROVIR
- Same area: Savacol Antiseptic Mouth & Throat Rinse
What it is
CLAVAMOX is a tablet containing amoxicillin (as trihydrate) 875 mg and clavulanic acid (as potassium) 125 mg.
Approved indications
The source documents provided do not contain information about the approved indications specific to the CLAVAMOX brand formulation (amoxicillin/clavulanic acid combination). The available product information relates to amoxicillin monotherapy formulations and does not detail the indications for the amoxicillin/clavulanic acid combination product.
Dosing overview
The source documents provided do not contain dosing information for the CLAVAMOX brand formulation (amoxicillin/clavulanic acid tablets).
Key safety warnings
The source documents provided do not contain information about key safety warnings for CLAVAMOX.
Contraindications
The source documents provided do not contain information about contraindications for CLAVAMOX.
PBS listing
The source documents provided do not contain information about PBS listing for CLAVAMOX.
Regulatory history
CLAVAMOX tablets 875 mg/125 mg (amoxicillin/clavulanic acid) were first registered on the ARTG on 14 November 2013.